Serum Institute to invest $ 100 million for TB vaccine, signs agreement with Gates MRI
The Gates MRI and Serum Institute of India have partnered to produce M72/AS01E, a promising TB vaccine pending Phase III trial results. This could be the first new TB vaccine in a century and a major breakthrough. SII will invest over $100 million to enhance manufacturing and was chosen for its track record in producing affordable and high-quality vaccines.